Understanding Osmotic Demyelination Syndrome

Osmotic demyelination syndrome (ODS), also called central pontine myelinolysis (CPM) and extra-pontine myelinolysis (EPM), is a demyelination of the pons region of the central nervous system that interrupts the flow of information within the brain and body.


R

Demyelination:

Destruction of myelin, the insulating layer around axons, essential for the proper functioning of the nervous system.
Demyelination

ODS is most often derived as a complication of treatment of patients with hypontremia (low serum sodium).


Correcting for hyponatremia too rapidly in the hospital can lead to:


myelin sheath

Acute damage of the myelin sheath in the pons area of the brain

Patient Care

Patient care is primarily supportive only

long-term disability

Serious long-term (chronic) disability and potentially death

No cure or treatment

There is no cure or specific treatment currently available


Clinical Signs and Symptoms


1

ODS is first diagnosed clinically and confirmed by MRI. However, it often takes days to several weeks after acute symptoms occur for confirmation of demyelination of the pons to be detected by MRI.


ODS Diagnosis
N

Acute Paralysis


N

Difficulty swallowing and / or speaking


N

Confusion, delirium, hallucinations


N

Balance problems, tremors


N

Reduced alertness, drowsiness, poor responses


2
Patients prone to hyponatremia include

Hyponatremia
N

Liver transplantation


N

Alcoholism


N

Severe Burns


N

Malnutrition

Treatment


There is no cure or specific treatment for ODS.
No treatment for ODS

q

Patients who develop ODS require long-term supportive care


q

There is no known cure or specific treatment

ENDECE Approach To Remyelination

ENDECE has discovered and is developing NDC-1308, a new therapy with a dual mechanism of action (MOA) designed to provide the necessary anti-inflammatory, pro-repair environment at lesions and upregulate genes necessary for inducing OPCs to differentiate into mature oligodendrocytes responsible for remyelination.

For more information go to About NDC-1308



NDC-1308

A new drug with a unique dual mechanism of action (MOA) for inducing remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis, neuromyelitis optica, and osmotic demyelination syndrome.


To request more information go to; ENDECE.com/contact